Medicilon Assists CGeneTech's Oral Hypoglycemic DPP-4 Inhibitor, New Drug Application (NDA) Accepted

Recently, CGeneTech (Suzhou) Co., Ltd. (CGeneTech) submitted the DPP-4 inhibitor, for the treatment of type 2 diabetes, to the National Medical Products Administration (NMPA) for approval.

Shanghai Medicilon Inc. (Medicilon), as a partner of CGeneTech, provided with comprehensive preclinical research services in compliance with GLP regulations, including pharmacodynamic research, pharmacokinetic research and safety evaluation, as well as Phase I clinical bioanalysis to facilitate its efficient and high-quality R&D.

Medicilon Preclinical Research Platform

Help drug research and development faster, better and cost-efficient

Efficiency comes from collaboration, and success comes from experience.  Medicilon, as a one-stop comprehensive preclinical research and development service CRO for biopharmaceutical, has been continuously improving the scientific and technological innovation for 19 years, providing customized preclinical test service solutions for various drugs, and have accumulated rich R&D experience in drug metabolism, pharmacokinetics, pharmacodynamics research, and toxicology.  With high-quality data and fast turnaround time, Medicilon preclinical research platform could help clients to develop their drugs faster, better and with less cost.

As early as 2009, the preclinical research laboratory of Medicilon's wholly-owned subsidiary, Medicilon Preclinical Research (Shanghai) LLC, obtained the certification of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) and reached the GLP standard of both US FDA and China’s NMPA, as well as the preclinical safety evaluation with the GLP specification of the Organization for European Economic Cooperation and Development (OECD).